Prevalence of Sleep Apnea and Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The investigators will screen consecutive patients presenting to the atrial fibrillation clinic for sleep apnea using a FDA-approved home sleep testing device, WatchPAT to determine prevalence of sleep apnea in a clinic-based sample.

Detailed Description
-----------------
The investigators will determine the prevalence of sleep apnea among consecutive patients with atrial fibrillation (AF) regardless of symptoms and determine the predictive value of screening tools for sleep apnea in this population. The primary outcome will be the prevalence of sleep apnea among all-comers with AF. Three secondary outcomes will be evaluated in the study. Investigators will determine the efficiency and time-to-diagnosis of sleep apnea using a FDA approved home sleep testing device (i.e. WatchPAT). These analyses will be compared to published studies performed using a traditional home sleep study test (which historically takes approximately 8-10 weeks). There will be no collection of data from a non-intervention group in our study. Second, investigtaors will calculate the predictive value of traditional clinical screening tools in an AF population using the STOP-BANG questionnaire and Epworth Sleepiness Scale. Third, investigators will identify potential risk factors for AF in patients with sleep apnea using a logistic regression model.

Official Title
-----------------
Prevalence of Sleep Apnea Among Consecutive Patients With Atrial Fibrillation.

Conditions
-----------------
Sleep Apnea, Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: WatchPAT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of AF confirmed on any electrocardiographic recording Age greater than or equal to 18 Ability to read and understand consent form, complete questionnaires, and provide informed consent Exclusion Criteria: Prior diagnosis of sleep disordered breathing or negative testing within the past 2 years without significant change in weight or clinical symptoms of sleep apnea History of Raynaud

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: WatchPAT|FDA-approved portable home sleep testing device worn on the wrist.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of sleep apnea | Prevalence of sleep apnea among patients with atrial fibrillation | 2 year study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to diagnosis | We will determine the efficiency and time-to-diagnosis of sleep apnea using a FDA approved home sleep testing device (i.e. WatchPAT) | 2 years | 
| Predictive value of typical screening tools | We calculate the predictive value of traditional clinical screening tools in an AF population using the STOP-BANG questionnaire and Epworth Sleepiness Scale | 2 years | 
| Quality of life | We will compare quality of life using the MAFSI in atrial fibrillation patients with and without sleep apnea. | 2 years | 
| Risk factors | We will identify potential risk factors for AF in patients with sleep apnea using a logistic regression model | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleep apnea, atrial fibrillation